Table 4.

Summary of clinical trials with primary analysis in psoriasis and additional analyses in subsets with nail psoriasis

Study drug	Study analysis	Dose	Mean % improvement in NAPSI
Infliximab, TNF‐α inhibitor16	Phase 3, RCT Retrospective	5 mg Q8W	W50, 67.8%
Etanercept, TNF‐α inhibitor15	Randomized, open‐label Post hoc	25 mg biw	W54, 51.0%
Ustekinumab, IL‐2/23 inhibitor18	Phase 2/3, RCT Secondary endpoint	45 mg and 90 mg Q12W	W64, 56.6% (45 mg) W64, 67.8% (90 mg)
Ixekizumab, IL‐17A inhibitor19	Phase 2, RCT Post hoc	120 mg Q4W	W48, 75.4%
Ixekizumab, IL‐17A inhibitor20	Phase 3, RCT Subgroup	80 mg Q4W	W60, 81.8%
Tofacitinib, JAK inhibitor21	Phase 3, RCT Post hoc	5 mg and 10 mg bid	W52, 65.6% (5 mg) W52, 75.5% (10 mg)

bid, twice daily; biw, twice weekly; eow, every other week; NAPSI, Nail Psoriasis Severity Index; Ps, psoriasis; RCT, randomized controlled trial; QnW, every n week(s); W, week.